Docetaxel: A therapeutic option in the treatment of cutaneous angiosarcoma : Report of 9 patients

✍ Scribed by Tohru Nagano; Yozo Yamada; Tetsuya Ikeda; Haruhisa Kanki; Tsuneyoshi Kamo; Chikako Nishigori

• Publisher: John Wiley and Sons
• Year: 2007
• Tongue: English
• Weight: 61 KB
• Volume: 110
• Category: Article
• ISSN: 0008-543X
• DOI: 10.1002/cncr.22822

✦ Synopsis

Abstract

BACKGROUND.

Effective treatment options are limited for patients with cutaneous angiosarcoma (AS). Docetaxel, a member of the taxane family of drugs, reportedly has been effective in the treatment of lung, head and neck, and breast cancers. Another taxane drug, paclitaxel, reportedly had unique activity in the treatment of AS of the scalp and neck and acquired immunodeficiency syndrome‐related Kaposi sarcoma. Therefore, the authors hypothesized that docetaxel may be of value in the treatment of cutaneous AS that is resistant to conventional therapy. However, there were only 3 case reports of the successful treatment of AS in elderly patients using docetaxel in combination with surgery and radiotherapy.

METHODS.

This was a retrospective trial. After written informed consent was obtained, docetaxel was administered intravenously at a dose of 25 mg/m^2^ for 1 hour weekly over a period of 8 weeks on the basis of previous reports. This treatment regimen was received by 9 patients with cutaneous AS who were treated at Kobe University Hospital between January 2003 and October 2006.

RESULTS.

Six of the 9 patients who received treatment achieved major responses, including 2 complete responses and 4 partial responses. Neutropenia and peripheral neuropathy were not prominent, although severe radiation dermatitis enhanced by the docetaxel was observed in 3 patients. There were no deaths attributable to this therapy.

CONCLUSIONS.

The current study demonstrated that docetaxel was effective in patients with cutaneous AS. Cancer 2007. © 2007 American Cancer Society.